Piper Sandler raised the firm’s price target on PacBio (PACB) to $2.50 from $2 following quarterly results. The firm keeps a Neutral rating on the shares.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB: